stockrowICON PLC
ICLR Healthcare Diagnostics & Research
ICON PLC’s revenue for fiscal 2025 (year ended December 2025) was $8.3 billion, up 0.76% from fiscal 2024.
- Revenue
- −2.86%
- EPS
- +143.2%
- Free cash flow
- −8.01%
- Total debt
- −0.86%
Quarter to September 2026, against a year earlier
Follow ICLR
Alert me
ICON PLC (ICLR) P/S ratio
As of 5 November 2026, ICON PLC (ICLR) trades at a P/S ratio of 1.9×. Over the past ten years it has ranged from 0.8× (February 2026) to 5.7× (December 2021); the current reading is higher than 14% of that period. That is below the Diagnostics & Research industry median of 4.2× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1.7× | (18.01%) |
| FY2024 | 2.1× | (25.60%) |
| FY2023 | 2.8× | 39.25% |
| FY2022 | 2.0× | (46.23%) |
| FY2021 | 3.8× | 2.92% |
| FY2020 | 3.7× | 11.45% |
| FY2019 | 3.3× | 22.73% |
| FY2018 | 2.7× | (23.56%) |
| FY2017 | 3.5× | 42.27% |
| FY2016 | 2.5× | (14.54%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 1.6× | (1.32%) |
| Jun 2026 | 1.6× | 57.06% |
| Mar 2026 | 1.0× | (40.83%) |
| Dec 2025 | 1.7× | 3.44% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| ICLR ICON PLC | 1.9× |
| LH Labcorp Holdings Inc. compare | 2.0× |
| DGX Quest Diagnostics Incorporated compare | 2.4× |
| CRL Charles River Laboratories International, Inc. compare | 3.8× |
| QGEN QIAGEN N.V. compare | 5.0× |
| RVTY Revvity Inc. compare | 5.7× |
| MEDP Medpace Holdings, Inc. compare | 6.2× |
| ILMN Illumina, Inc. compare | 7.0× |
| GH Guardant Health, Inc. compare | 16.2× |
| Diagnostics & Research industry median | 4.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on ICLR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement